This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Fibrates act to attenuate atherogenic dyslipidemia in type 2 diabetic patients.
However an increase of serum homocysteine (tHcy) after fenofibrate treatment
has been reported, compromising its cardiovascular benefit. Polymorphisms in
candidate genes related to lipid, lipoprotein and tHcy metabolisms were suspected to
influence this response. The association between polymorphisms in cholesteryl ester
transfer protein (CETP), apolipoprotein A5 (apo A 5), and methylenetetrahydrofolate
reductase (MTHFR) genes in response to fenofibrate treatment ((200 M) for 4 weeks
was evaluated in twenty one type 2 diabetic patients.
After fenofibrate use a significant decrease of TG level (29%) and a decrease of
total cholesterol (p = 0.081) and CETP activity (p = 0.089) were noted. However,
the HDL-C concentration has increased (p= 0.081) while LDL-C levels did not vary.
Moreover, the prevalence of hyperhomocysteinemia, rose to 100%.
Both apo A5 TT and TC carriers showed significant decrease of TG levels. Whereas
the HDL-C variation is better in TT genotype (23.5% vs -1.3% for TT and TC
respectively; p = 0.062). The decrease of TG levels after fenofibrate treatment is
more important in B1B1 than in B2B2 genotype of CETP polymorphism. Only B1B1
homozygous showed a decrease of CETP activity and an increase of HDL-C. After
fenofibrate use, the increase of tHcy levels was more important in MTHFR T carriers
than in CC homozygous (39.97 � 14.77 vs. 28.02 � 8.59 μmol/l, respectively).
Pharmacogenomic studies have a great economic and health interest for a better
treatment of type 2 diabetic patients.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals